Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI: A Meta-Analysis

CONTENT: Clopidogrel, one of the most commonly prescribed medications, is a pro-drug requiring CYP450 biotransformation. Data suggest its pharmacologic effect varies based on CYP2C19 genotype, but there is uncertainty regarding the clinical risk imparted by specific genotypes. OBJECTIVE: In patients...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Mega, Jessica L., Simon, Tabassome, Collet, Jean-Philippe, Anderson, Jeffrey L., Antman, Elliott M., Bliden, Kevin, Cannon, Christopher P., Danchin, Nicolas, Giusti, Betti, Gurbel, Paul, Horne, Benjamin D., Hulot, Jean-Sebastian, Kastrati, Adnan, Montalescot, Gilles, Neumann, Franz-Josef, Shen, Lei, Sibbing, Dirk, Steg, P. Gabriel, Trenk, Dietmar, Wiviott, Stephen D., Sabatine, Marc S.
Formato: Artigo
Idioma:Inglês
Publicado: 2010
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3048820/
https://ncbi.nlm.nih.gov/pubmed/20978260
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2010.1543
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares